ČESKÁ UROLOGIE / CZECH UROLOGY – 4 / 2021

242 Ces Urol 2021; 25(4): 236–243 PŘEHLEDOVÝ ČLÁNEK 17. EAU Guidelines: Prostate Cancer. [online] 2021 [cit 16-8-2021] Dostupné z: https://uroweb org/gui‑ deline/prostate‑cancer/ 18. Nordström T, Akre O, Aly M, Grönberg H, Eklund M. Prostate‑specific antigen (PSA) density in the diagnostic algorithm of prostate cancer Prostate Cancer Prostatic, DiS 2018; 21(1): 57–63 19. Arlen, PM, Bianco F, Dahut WL, et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time J Urol 2008; 179: 2181 20. Vickers AJ, Savage C, O’Brien MF, et al. Systematic review of pretreatment prostatespecific antigen velocity and doubling timeas predictors for prostate cancer J Clin Oncol 2009; 27: 398–403 21. PRIAS Project [online]. 2021 [cit 16-8-2021] Dostupné z: https://prias‑project org/modules/articles/ article php?id=1 22. Christensson A, Bjork T, Nilsson O, et al. Serum prostate specific antigen complexed to alpha 1 anti‑ chymotrypsin as an indicator of prostate cancer J Urol 1993; 150: 100–105 23. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate‑specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial JAMA 1998; 279(19): 1542–1547 24. Stephan C, Lein M, Jung K, et al. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia Cancer 1997; 79: 104 25. Huang Y, Li ZZ, Huang YL, et al. Value of free/total prostate‑specific antigen (f/t PSA) ratios for pro‑ state cancer detection in patients with total serum prostate‑specific antigen between 4 and 10 ng/mL: A metaanalysis Medicine (Baltimore) 2018; 97: 0249 26. Fiala V, Hanuš T, Čapoun O, et al. Zkušenosti s použitím indexu zdraví prostaty v klinické praxi Ces Urol 2017; 21(4): 284–288 27. Le BV, Griffin CR, Loeb S, et al. [-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 2010; 183: 1355–1359 28. Lazzeri M, Haese A, Abrate A, et al. Clinical performance of serum prostate specific antigen isoform [−2]proPSA (p2PSA) and its derivatives %p2PSA and the prostate health index (phi) in men with a family history of prostate cancer: results from a multicenter European study, the PROMEtheuS project BJU Int 2013; 112: 313–321 29. Ryšánková K, Bartoš V, Krhut J, et al. (-2)proPSA a Index zdravé prostaty (PHI) v predikci výskytu kar‑ cinomu prostaty v transrektálních biopsiích Ces Urol 2018; 22(1): 40–47 30. Fuchsová R, Topolčan O, Hora M, et al. Přínos stanovení [-2]proPSA v diferenciální diagnostice karci‑ nomu prostaty Ces Urol 2014; 18(1): 21–25 31. Catalona W, Partin A, Bangma C, et al. A multicenter study of [-2]pro‑prostate specific antigen com‑ bined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2 0 to 10 0 ng/ml prostate specific antigen range J Urol 2011; 185: 1650–1655 32. Haese A, Graefen M, Steuber T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organconfined from locally‑advanced prostate cancer in total PSA‑levels below 10 ng/ ml Prostate 2001; 49(2): 101–109 33. Gupta A, Roobol MJ, Savage CJ, et al. A four‑kallikrein panel for the prediction of repeat prostate bio‑ psy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands Br J Cancer 2010; 103(5): 708–714 34. Novák V, Veselý Š. PSA a jeho izoformy jako moderní markery karcinomu prostaty Ces Urol 2019; 23(3): 194–202